OTC Markets EXMKT - Delayed Quote USD
Vaxxinity, Inc. (VAXX)
As of 10:18 AM EDT. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
--
--
--
66.0000
557.0000
--
Cost of Revenue
--
--
--
1,937.0000
52.0000
--
Gross Profit
--
--
--
-1,871.0000
505.0000
--
Operating Expense
58,285.0000
58,285.0000
75,979.0000
123,204.0000
32,787.0000
--
Operating Income
-58,285.0000
-58,285.0000
-75,979.0000
-125,075.0000
-32,282.0000
--
Net Non Operating Interest Income Expense
1,394.0000
1,394.0000
745.0000
-831.0000
-1,181.0000
--
Other Income Expense
-43.0000
-43.0000
12.0000
-11,269.0000
-6,494.0000
--
Pretax Income
-56,934.0000
-56,934.0000
-75,222.0000
-137,175.0000
-39,957.0000
--
Tax Provision
--
--
--
--
--
56.0000
Net Income Common Stockholders
-56,934.0000
-56,934.0000
-75,222.0000
-137,175.0000
-39,957.0000
--
Diluted NI Available to Com Stockholders
-56,934.0000
-56,934.0000
-75,222.0000
-137,175.0000
-39,957.0000
--
Basic EPS
-0.45
--
-0.60
-1.79
-0.32
-0.11
Diluted EPS
-0.45
--
-0.60
-1.79
-0.32
-0.11
Basic Average Shares
126,508.9170
--
125,939.0500
76,586.8420
124,753.1780
124,753.1780
Diluted Average Shares
126,508.9170
--
125,939.0500
76,586.8420
124,753.1780
124,753.1780
Total Operating Income as Reported
-58,285.0000
-58,285.0000
-75,979.0000
-125,075.0000
-32,282.0000
--
Total Expenses
58,285.0000
58,285.0000
75,979.0000
125,141.0000
32,839.0000
--
Net Income from Continuing & Discontinued Operation
-56,934.0000
-56,934.0000
-75,222.0000
-137,175.0000
-39,957.0000
--
Normalized Income
-56,891.0000
-56,891.0000
-75,234.0000
-125,906.0000
-33,463.0000
--
Interest Income
2,090.0000
2,090.0000
1,259.0000
9.0000
1.0000
--
Interest Expense
696.0000
696.0000
514.0000
840.0000
1,182.0000
--
Net Interest Income
1,394.0000
1,394.0000
745.0000
-831.0000
-1,181.0000
--
EBIT
-56,238.0000
-56,238.0000
-74,708.0000
-136,335.0000
-38,775.0000
--
EBITDA
-54,004.0000
-54,004.0000
-73,024.0000
-135,233.0000
-38,058.0000
--
Reconciled Cost of Revenue
--
--
--
1,937.0000
52.0000
--
Reconciled Depreciation
2,234.0000
2,234.0000
1,684.0000
1,102.0000
717.0000
--
Net Income from Continuing Operation Net Minority Interest
-56,934.0000
-56,934.0000
-75,222.0000
-137,175.0000
-39,957.0000
--
Total Unusual Items Excluding Goodwill
-43.0000
-43.0000
12.0000
-11,269.0000
-6,494.0000
--
Total Unusual Items
-43.0000
-43.0000
12.0000
-11,269.0000
-6,494.0000
--
Normalized EBITDA
-53,961.0000
-53,961.0000
-73,036.0000
-123,964.0000
-31,564.0000
--
12/31/2019 - 11/11/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ACIU AC Immune SA
3.0550
-0.49%
NKGNW NKGen Biotech, Inc.
0.0432
+5.37%
NRBO NeuroBo Pharmaceuticals, Inc.
3.0000
+3.45%
NKGN NKGen Biotech, Inc.
0.3980
-11.79%
PBMWW Psyence Biomedical Ltd.
0.0360
-8.76%
PXMD PaxMedica, Inc.
0.1400
+4.09%
SEEL Seelos Therapeutics, Inc.
1.2000
+6.19%
DNLI Denali Therapeutics Inc.
26.65
+1.02%
CERO CERo Therapeutics Holdings, Inc.
0.0833
-4.15%
VIGL Vigil Neuroscience, Inc.
3.7500
-2.34%